Journal of Antimicrobial Chemotherapy · 2005 · 31 citations · 25 references
Life SciencesMicrobiologyPharmacologyAntimicrobial ResistanceMedical MicrobiologyMycologyAntifungal AgentsAntifungal PharmacologyAntifungal ResistanceAntifungal TherapyFungal InfectionsFungal PathogenesisAntifungal AntibioticsAntifungal ChemotherapyAntifungal PharmacodynamicsAntifungal TreatmentsCandida Albicans InfectionCandida TherapyCandidiasis Drug ResistanceNew Antifungal Agents
OBJECTIVES: The in vitro antifungal activity of posaconazole was compared with that of fluconazole and amphotericin B. MATERIALS AND METHODS: A microdilution method (M27-A2) was used with 331 clinical yeast isolates. RESULTS: The geometric mean MICs of posaconazole, fluconazole and amphotericin B were 0.16, 0.91 and 0.15 mg/L, respectively. Posaconazole was markedly more active than fluconazole and was active against 9/11 fluconazole-resistant Candida albicans, and five Candida glabrata had an MIC of posaconazole of 16 mg/L. CONCLUSIONS: These data indicate that posaconazole is a potentially effective antifungal agent for the treatment of mycoses caused by yeasts.
25
Ana Espinel‐Ingroff · Journal of Clinical Microbiology · 1998 · 577 citations · Full text
Life Sciences, Biology, Microbiology +11
Michael A. Pfaller, S. A. Messer, R. J. Hollis et al. · Antimicrobial Agents and Chemotherapy · 2002 · 402 citations · Full text
Medicine, Microbiology, Pharmacology +17